Advertisement

Betarezeptorenblocker

  • Björn Lemmer

Zusammenfassung

Betarezeptorenblocker spielen eine wichtige Rolle bei der Behandlung kardiovaskulärer Krankheiten. Hauptindikationen sind arterielle Hypertonie, koronare Herzkrankheit, tachykarde Herzrhythmusstörungen und chronische Herzinsuffizienz. Wichtigste Gruppe sind die β1-selektiven Betarezeptorenblocker.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aursnes I, Osnes J-B, Tvede IF, Gasemyr J, Natvig B (2007): Does atenolol differ from other ß-adrenergic blockers? BMC Clin Pharmacol 7:4PubMedCentralPubMedCrossRefGoogle Scholar
  2. Arzneimittelkommission der deutschen Ärzteschaft (2009): 23. Arterielle Hypertonie: Arzneiverordnungen. 22. Aufl., Medizinische Medien Informations GmbH, Neu-Isenburg: S 597–628Google Scholar
  3. Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP (2013): Sytematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol 168: 3572–3579PubMedCentralPubMedCrossRefGoogle Scholar
  4. Bell DS, Lukas MA, Holdbruck FK, Fowler MB (2006): The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. Curr Med Res Opin 22: 287–296PubMedCrossRefGoogle Scholar
  5. Bowman AJ, Chen CP, Ford GA (1994): Nitric oxide mediated venodilator effects of nebivolol. Brit J Clin Pharmacol 38: 199–204CrossRefGoogle Scholar
  6. Chatterjee S, Biondi-Zoccai G, Abbate A, D’Ascenzo F, Castagno D, Van Tassell B, Mukherjee D, Lichstein E (2013): Benefits of ß blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ 346: f55. doi: 10.1136/bmj.f55PubMedCentralGoogle Scholar
  7. Chobanian AV, et al (2004): Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute;. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7). NIH No.04-5230, update of the JNC7 Report. http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf. Aufgerufen 29.4.2011
  8. CIBIS II Study (1999): The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet 353: 9–13Google Scholar
  9. Contini M, Apostolo A, Cattadori G, Paolillo S, Iorio A, Bertella E, Salvioni E, Alimento M, Farina S, Palermo P, Louercio M, Manzegazza V, Karten M, Sciomer, S, Magri D, Fiorentini C, Agpstini P (2013). Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: The CARNEBI trial. Int J Cardiol 168: 2134–2140PubMedGoogle Scholar
  10. Dargie HJ (2003): b-Blockers in heart failure. Lancet 362: 2–3PubMedCrossRefGoogle Scholar
  11. Deutsche Hochdruckliga – Deutsche Hypertonie Gesellschaft (2008): Leitlinien zur Behandlung der arteriellen Hypertonie. Stand Juni 2008. http://www.leitlinien.net/046-001.pdf
  12. Deutsche Hochdruckliga, Deutsche Gesellschaft für Hypertonie und Prävention. (2011). DHLLeitlinien-update 2011. http://www.hochdruckliga.de/tl_files/content/dhl/downloads/DHL-Leitlinien-2011.pdf
  13. DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O‘Keefe JH (2013). Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol). Am J Cardiol 111: 765–769PubMedCrossRefGoogle Scholar
  14. Eschenhagen T, Erdmann E (2010): 16. Herzinsuffizienz. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie - Klinische Pharmakologie, 14. Auflage, Springer, Heidelberg New York, S. 229–243Google Scholar
  15. Flather MC, Shibata MC, Coats AJS et al (2005): Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26: 215–225PubMedGoogle Scholar
  16. Grundt C, Meier K, Grundt A, Lemmer B (2007): Evidence for an estradiol-agonistic action of nebivolol in spontaneously hypertensive rats. J Hypertens 25: 1001–1007Google Scholar
  17. Hohlfeld T, Kelm M (2010): 17. Koronare Herzkrankheit. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie - Klinische Pharmakologie, 14. Auflage, Springer, Heidelberg New York, S. 245–257Google Scholar
  18. Hop pe UC, Erdmann E (2010): Herzinsuffizienz Update 2010 und aktuelle ESC-Leitlinien. Herz 35: 535–541CrossRefGoogle Scholar
  19. Kreutz R, Kolloch R (2010): Arterielle Hypertonie. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie - Klinische Pharmakologie, 14. Auflage, Springer Verlag, Berlin Heidelberg New York, S. 197–218Google Scholar
  20. Lindholm LH, Carlberg B, Samuelsson O (2005): Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366: 1545–1553PubMedCrossRefGoogle Scholar
  21. McMurray J (2005): Making sense of SENIORS. Eur Heart J 26: 203–206PubMedGoogle Scholar
  22. M ERIT-HF Study (1999): Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure. Lancet 353: 2001–2007Google Scholar
  23. Mo en MD, Wagstaff AJ (2006): Nebivolol – a review of its use in the management of hypertension and chronic heart failure. Drugs 66: 1389–1409PubMedGoogle Scholar
  24. National Institute of Health and Clinical Excellence (NICE) (2006): Management of hypertension in adults in primary care: partial update. Im Internet unter: guidance.nice.org.uk/CG34/niceguidance/pdf/EnglishGoogle Scholar
  25. Packer M, Coats AJS, Fowler MB, Katus HA et al (2001): Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651–1658PubMedCrossRefGoogle Scholar
  26. Poole- Wilson PA, Svedberg K, Cleland JGF, Lenarda A, Hanrath P, Komajda M et al (2003): Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362: 7–13PubMedGoogle Scholar
  27. POI SE Study Group (2008): Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial) a randomized controlled trial. Lancet 371: 1839–1847Google Scholar
  28. Programm für nationale Versorgungsleitlinie. (2012). Chronische Herzinsuffizienz. pp. http://www.versorgungsleitlinien.de/themen/herzinsuffizienz/pdf/nvl_hi_kurz.pdf
  29. Sackner-Bernstein J (2005): Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapy. Clin Cardiol 28 (11 Suppl 1): I19–27Google Scholar
  30. Salpeter S, Ormiston T, Salpeter E, Wood-Baker R (2006): Cardioselective beta-blockers for reversible airway disease. The Cochrane Library, The Cochrane Collaboration Volume (1), 2006Google Scholar
  31. Tzemos N, Lim PO, MacDonald TM (2001): Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 104: 511–514PubMedCrossRefGoogle Scholar
  32. Vestbo J, Hurd SS, Augusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. (2013). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. Am J Respir Crit Care Med. 187: 347–365PubMedCrossRefGoogle Scholar
  33. Wiysonge CS, Bradley HA, J V, Mayosi MB, Mbewu A, Opie LH. (2012). Beta-blockers for hypertension. Cochrane Database Syst Rev. Nov 14: CD00200–3Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Björn Lemmer
    • 1
  1. 1.Institut für Pharmakologie und Toxikologie, Fakultät für Klinische Medizin MannheimUniversität HeidelbergWürzburg

Personalised recommendations